Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Major Shareholder Sells 1,016,823 Shares

Posted by Grant Hamersma on Oct 5th, 2024

Conduit Pharmaceuticals Inc. (NASDAQ:CDT – Get Free Report) major shareholder Ltd Nirland sold 1,016,823 shares of Conduit Pharmaceuticals stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $0.12, for a total value of $122,018.76. Following the completion of the sale, the insider now directly owns 11,483,177 shares in the company, valued at approximately $1,377,981.24. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Ltd Nirland also recently made the following trade(s):

On Wednesday, October 2nd, Ltd Nirland sold 333,177 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.10, for a total transaction of $33,317.70.

Conduit Pharmaceuticals Price Performance

CDT stock opened at $0.10 on Friday. Conduit Pharmaceuticals Inc. has a one year low of $0.10 and a one year high of $7.83. The company has a fifty day moving average price of $0.15 and a two-hundred day moving average price of $1.56.

Conduit Pharmaceuticals (NASDAQ:CDT – Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.07) earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Berenberg Bank raised Conduit Pharmaceuticals to a “strong-buy” rating in a report on Friday, July 26th.

Check Out Our Latest Research Report on Conduit Pharmaceuticals

Conduit Pharmaceuticals Company Profile

(Get Free Report)

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.